ClinicalTrials.gg
RecruitingNCT05783375ADUNUUpdated May 15, 2026

Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda

An interventional study of ADUNU program for delivery of RHD care services in Rheumatic Heart Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in Uganda. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
221
Allocation
Not applicable
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 7 under way, 2 of them phase 3. Rheumatic Heart Disease · Children's Hospital Medical Center, Cincinnati.

Planned enrollment
7th of 10
221 · median 629
Started
2024
with 1 other
No phase
7 of 13
3 open now
Registered
6th of 13
by date

Among the 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 with no phase, and was the 6th registered.

Rheumatic Heart Disease

62 studies on the registry are indexed under Rheumatic Heart Disease; 26 are open to participants now.

Browse Rheumatic Heart Disease studies →

Open to participants now

7 of the 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 11 Rheumatic Heart Disease studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 5 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

The goal of this prospective study is to evaluate the feasibility, sustainability, and public health impact of a district-based program for secondary prevention of Rheumatic Heart Disease (RHD) in Uganda.

Read the detailed description

ADUNU is a non-randomized experiment, testing a strategy for implementing an evidence-based practice, decentralized RHD preventive services.

The objectives of the study are to:

Objective 1: Demonstrate the impact of ADUNU, using the RE-AIM framework to assess program Reach, Effectiveness, Adoption, Implementation and Maintenance.

Objective 2: Estimate the cost-effectiveness and budget impact of ADUNU.

ADUNU is a public health initiative that will be deployed the Uganda ministry of health in partnership with the District Health Offices (DHO) in two districts. The program will be overseen by the Technical and Quality Assurance (TAQA). ADUNU's main components will include a RHD testing program which consists of community and facility based echocardiographic screening of children and young adults and a registry based secondary prophylaxis injections of Benzathine penicillin G (BPG) at local health centers III and IVs in both districts.

03

Conditions studied

  • Rheumatic Heart Disease
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • residing in one of two involved districts in Uganda
  • providers at HCIIIs and HCIVs located in one of two involved Ugandan districts

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
221 participants (estimated)

Study arms

  • Other
    ADUNU Participants

    Individuals and healthcare providers residing and working in the involved Ugandan Districts.

    Other: ADUNU program for delivery of RHD care services

Interventions

  • OtherADUNU program for delivery of RHD care services

    The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.

06

What researchers measure

Primary outcomes

  1. Proportion of persons with RHD reached by the ADUNU program

    This objective will involve only secondary analysis of de-identified data collected by districts using routine MOH data collection procedures supplemented by some routine program data during the Ministry's rollout of the ADUNU Programme Package. The number of individuals screened and screening positivity rates will be extracted from screening logs implemented and maintained by DHOs and assessed by modality (school fairs, health days, passive health center screening, and active outreach to family members of RHD diagnosed).

    Time frame: 5 year endpoint

  2. Proportion of persons with RHD enrolled in care, retained and adherent to treatment

    Secondary analysis of data from the districts RHD registry will be used to assess the proportion of registrants enrolled, retained and adherent to secondary prophylaxis.

    Time frame: 3 months

  3. Proportion of persons with RHD enrolled in care, retained and adherent to treatment

    Secondary analysis of data from the districts RHD registry will be used to assess the proportion of registrants enrolled, retained and adherent to secondary prophylaxis.

    Time frame: 24 months

  4. Adoption and implementation of the ADUNU program at the organization level surveys

    Brief surveys will be filled out by providers who are acting as administrators of their health centre and will include questions on a range of logistic (e.g., availability of commodities and stockouts, basic infrastructure reliability) and organizational readiness topics (e.g., staffing levels and turnover, organization of patient scheduling, district support visits)

    Time frame: Baseline

  5. Adoption and implementation of the ADUNU program at the organization level surveys

    Brief surveys will be filled out by providers who are acting as administrators of their health centre and will include questions on a range of logistic (e.g., availability of commodities and stockouts, basic infrastructure reliability) and organizational readiness topics (e.g., staffing levels and turnover, organization of patient scheduling, district support visits)

    Time frame: 24 months

  6. Adoption and implementation of the ADUNU program at the provider level

    Two types of data collection activities from frontline providers will be used to understand individual provider-level adoption and maintenance over time: provider surveys and in-depth interviews of providers. A standardized survey instrument on Adoption and a standardized checklist on implementation fidelity that will be completed by the research staff via direct observation. Research staff will use a standardized checklist that will be developed from the core elements of RHD testing (e.g., ultrasound technique, saving of images) and secondary prevention (e.g., injection technique, adequate post-injection monitoring for anaphylaxis)

    Time frame: 6 months

  7. Adoption and implementation of the ADUNU program at the patient level interview

    We will conduct a limited number of interviews of registry patients in each district stratified by adherence outcomes as well as age group (adult vs children).

    Time frame: 24 months

  8. Cost-analysis of the ADUNU program

    To estimate program costs, we will use the standardized data collection instruments. Our instruments will measure fixed and capital costs, as well as variable or recurrent costs. Ingredients-based costing will be used for drugs and consumables, personnel costs, and equipment costs, whereas gross costing will be used for "indirect" costs such as facility rents and utilities and maintenance. Relevant data for ingredients-based costing include study data on participant healthcare utilization and price lists of drugs, consumables, and equipment. DHO budget sheets for health facilities and overall health service utilization will be used for gross costing. Both financial costs and economic costs will be measured. We will also estimate of out-of-pocket costs borne by registrants, which will allow us to estimate costs from the patient/household perspective.

    Time frame: 3 year endpoint

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Mar 24, 2023
StartActual
May 1, 2024
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2028
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05783375
Collaborators
Uganda Heart Institute
Responsible party
Sponsor
First posted
Mar 24, 2023
Start date
May 1, 2024
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
May 15, 2026

Study contacts

Ndate Fall
Contact
ndate.fall@cchmc.org
15135171327
Mary Banks
Contact
mary.Banks@cchmc.org
Andrea Z Beaton
principal investigator · Cincinnati Chidren's hospital
Emmy H Okello
principal investigator · Uganda Heart Institute
David Watkins
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion